| Sign In to gain access to subscriptions and/or personal tools. |
2-Butoxyethanol Female-Rat Model of Hemolysis and Disseminated Thrombosis: X-Ray Characterization of Osteonecrosis and Growth-Plate Suppression
1 Laboratory of Experimental Pathology Correspondence: Address correspondence to: Dr. Abraham Nyska, Laboratory of Experimental Pathology, MD B3-06, National Institute of Environmental Health Sciences, 111 T. W. Alexander Drive, Research Triangle Park, North Carolina 27709-9998, USA; e-mail:nyska{at}niehs.nih.gov.
We recently proposed a chemically induced rat model for human hemolytic disorders associated with thrombosis. The objective of the present investigation was to apply a noninvasive, high-magnification X-ray analysis, the Faxitron radiography system, to characterize the protracted bone damage associated with this 2-butoxyethanol model and to validate it by histopathology. Groups of female Fischer 344 rats were given 0, 250, or 300 mg of 2-butoxyethanol/kg body weight daily for 4 consecutive days. Groups were then sacrificed 2 hours or 26 days after the final treatment. The treated animals displayed a darkened purple-red discoloration on the distal tail. Histopathological evaluation, including phosphotungstic acid-hematoxylin staining of animals sacrificed 2 hours after the final treatment, revealed disseminated thrombosis and infarction in multiple organs, including bones. The Faxitron MX-20 specimen radiography system was used to image selected bones of rats sacrificed 26 days posttreatment. Premature thinning of the growth plate occurred in the calcaneus, lumbar and coccygeal vertebrae, femur, and ilium of the treated animals. Areas of decreased radiographic densities were seen in the diaphysis of the femur of all treated animals. The bones were then examined histologically and showed a range of changes, including loss or damage to growth plates and necrosis of cortical bone. No thrombi were seen in the animals sacrificed at 30 days, but bone and growth plate changes consistent with prior ischemia were noted. The Faxitron proved to be an excellent noninvasive tool that can be used in future studies with this animal model to examine treatment modalities for the chronic effects of human thrombotic disorders.
Key Words: 2-Butoxyethanol • hemolysis • thrombosis • osteonecrosis • growth plate • ischemia Abbreviations: BAA, 2-butoxyacetic acid • BE, 2-butoxyethanol • H&E, hematoxylin and eosin • Hct, hematocrit • Hgb, hemoglobin • MCH, mean cell hemoglobin • MCHC, mean cell hemoglobin concentration • MCV, mean cell volume • MRI, magnetic resonance imaging • NBF, neutral buffered formalin • PCV, packed cell volume • PTAH, phosphotungstic acid-hematoxylin • RBC, red blood cells • WBC, white blood cells 2-Butoxyethanol (BE) is a major environmental chemical utilized in the manufacturing of a wide range of domestic and industrial products, including surface coatings and household cleaning agents (Nyska et al., 1999b). It has been shown to cause acute hemolytic anemia in Fischer 344 rats upon metabolic activation to 2-butoxyacetic acid (BAA), with the hemolysis occurring more rapidly and severely in female rats (Ghanayem et al., 2000; Ezov et al., 2002). After 3 to 4 days of exposure to the chemical, thrombosis becomes apparent in several organs in the female rats, including the cardiac atrium, lungs, brain, submucosa of the anterior nasal septum, pulp of the incisor teeth, liver, coccygeal vertebrae, and femur (Nyska et al., 1999a, 1999b; Long et al., 2000; Ezov et al., 2002; Redlich et al., 2004). In addition, acute infarction occurs in the coccygeal vertebrae of the affected females, including that of the growth plate, and necrosis is seen grossly in the distal third of the tail (Nyska et al., 1999b; Shabat et al., 2004). This acute and disseminated thrombosis and infarction in female rats induced by BE may result from vaso-occlusion, possibly triggered by acute hemolytic anemia with the potential release of procoagulant factors from destroyed erythrocytes, altered morphology and decreased deformability of erythrocytes, and a tendency of the red blood cells to aggregate and/or adhere to the endothelium (Ghanayem et al., 2000; Koshkaryev et al., 2003; Nyska et al., 2003). The lack of bone or vascular lesions in male rats may be due to a more efficient elimination of BAA or decreased activity of aldehyde dehydrogenase, the enzyme responsible for the conversion of BE to its active metabolite (Aasmoe et al., 1998; Dill et al., 1998). In addition, less mature red blood cells have been shown to be more resistant to the effects of BE (Ghanayem et al., 2000; Koshkaryev et al., 2003). Human erythrocytes are much less sensitive to the effects of BE than those of rats, requiring 100 times the concentration of BAA to develop fragility (Udden, 2002). The target organs for thrombosis and infarction found in this model, however, are similar to those observed in human disorders characterized by hemolysis and thrombosis, such as thalassemia and sickle cell disease (Smith, 1996; Eldor and Rachmilewitz, 2002; Ezov et al., 2002; Shabat et al., 2004). Furthermore, enhanced red blood cell and endothelial cell interaction has been demonstrated both in this animal model and human thrombotic diseases (Hovav et al., 1999; Yedgar et al., 1999; Koshkaryev et al., 2003). Currently, no effective or easy treatment exists for these conditions in man (Smith, 1996; Reed and Vichinsky, 1998; Eldor and Rachmilewitz, 2002). Previous animal models for these diseases have been either invasive or ineffective (Norman et al., 1998). This rat model of disseminated thrombosis induced by BE is a novel and noninvasive tool mimicking human hemolytic disorders associated with thrombosis. Magnetic resonance imaging (MRI) has been used recently to study BE-induced bone injury in these rats. The MRI examination, however, neither identified a specific lesion nor distinguished the growth plate and diaphysis of the vertebrae (Shabat et al., 2004). That normal radiographs are not adequate for the diagnosis of aseptic osteonecrosis in human thrombotic diseases, such as sickle cell disease (Smith, 1996), has been demonstrated. The need exists, therefore, for a high-resolution imaging technique to aid in the diagnosis of this disease manifestation. Our goal was to determine whether a noninvasive, high-magnification X-ray imaging system, Faxitron MX-20 Digital, could reveal the bone lesions related to ischemia and thrombosis in the BE rat model. We hypothesized that the Faxitron could be applied to this animal model, providing high-quality images that could be used in additional applications testing various treatment modalities for the prevention of chronic complications of hemolytic disorders associated with thrombosis, such as bone infarction that occurs in thalassemia and sickle cell disease. Female Fischer 344 rats were treated with either 250 or 300 mg/kg body weight of BE for 4 consecutive days. The dose of 250 mg/kg was shown in previous experiments (Ezov et al., 2002) to be the most appropriate dose to produce disseminated thrombosis. A dosage of 300 mg/kg was utilized to determine whether more widespread and severe alterations would develop in the skeleton secondarily to an increased incidence of thrombosis. Ghanayem et al. (1990) performed acute exposure toxicokinetic studies with BE administered as an IV bolus to 3–4-month-old male Fischer rats at doses of 31.35, 62.5, and 125.0 mg/kg; (dose volume = 1 ml/kg). Results indicated the Cmax, AUC and Cl8 of BE and BAA (the proximate metabolite of BE). Cmax and AUC were increased, whereas Cl8 decreased as the BE dose increased. These results suggested that the administration of 300 mg/kg would result in a higher Cmax and AUC than would 250 mg/kg. The bones were examined histologically immediately after the final dose and by radiography and subsequent histology 26 days later. Our findings indicate a strong correlation between histological alterations and X-ray images, suggesting that the Faxitron imaging system possesses the sensitivity and specificity to detect bone lesions in this chemically induced model of disseminated thrombosis and bone necrosis in rats.
Chemicals, Animals, Treatments, and Experimental Procedures 2-Butoxyethanol of >99% purity was purchased from Sigma-Aldrich Chemical Co. (Rehovot, Israel). Female F344 rats 11 weeks of age were obtained from Taconic Farms (Germantown, NY) and provided the NTP 2000 diet (Zeigler Brothers, Gardners, PA) and water ad libitum. The animals were singly housed and allowed a period of acclimation to the facility conditions (18–26°C, 30–70% relative humidity, 12-hour light/dark cycle) before beginning the study. All procedures, care, and treatment of the rats were in accordance with the principles for humane treatment outlined by the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (Institute of Laboratory Animal Resources, 1996). The study was conducted following the review and approval of the Committee for Ethical Conduct in the Care and Use of Laboratory Animals at Integrated Laboratory Systems (ILS, Research Triangle Park, North Carolina 27709, USA) and after being found in compliance with the rules and regulations set forth. Control animals used in the X-ray analyses were derived from a previous BE study. The animal husbandry in the study was the same except for the age of the rats, which were 6–7 weeks old at the initiation of the experiment. Dosing solutions of BE were prepared daily immediately prior to each dosing by mixing with tap water to obtain a dose volume of 5 ml/kg body weight and administered to the rats by gavage. Oral administration of BE is known to induce thrombosis in rats and is therefore the best available method of dosing. At study commencement, test groups were administered either 250 or 300 mg BE/5 ml tap water/kg body weight (Table 1). Control groups were administered tap water only. Animals were randomly assigned to treatment groups using a by-body-weight stratification procedure. Test groups received 4 consecutive daily treatments; the first day of dosing was regarded as day 1. The animals were observed approximately 24 hours after each dose and body weights were measured just prior to the first dosing and at termination.
Animals were sacrificed by CO2 asphyxiation. Animals from groups 1, 2, and 3 were sacrificed and necropsied approximately 2 hours after the fourth dose. Animals from groups 4, 5, and 6 were sacrificed and necropsied at 30 days (26 days after the final treatment). From each animal euthanized 2 hours after the fourth dose, blood was immediately collected from the retroorbital venous plexus and placed into EDTA tubes. The following hematological parameters were evaluated: red blood cell (RBC) and white blood cell (WBC) counts, hemoglobin concentration (Hgb), hematocrit (Hct), mean cell volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), platelet count, and packed cell volume (PCV). For the cell blood count, the samples were assayed using the Technicon H-1 hematology analyzer (Bayer Corporation, Tarrytown, NY). To monitor RBC parameters, spun microhematocrit was determined for each specimen and compared with automated hematocrit, which was calculated from the directly measured RBC and MCV. Control products were assayed after every specimen. For WBC differential data, Wright-Giemsa-stained smears were prepared, and manual WBC differential counts were performed on at least the first sample in the control group, as well as any other samples with an abnormal count. Manual differentials were performed on all smears from treated animals. In cases in which the two counts did not agree, the manual value was reported. RBC and platelet morphology was also examined. The blood smears were stained using the Ames Hema-Tek II automated slide stainer (Bayer Corporation, Ames Division, Elkhart, IN) For reticulocyte counts, equal amounts of whole blood and New Methylene Blue stain were allowed to incubate at room temperature for at least 15 minutes. Blood smears were prepared and examined to determine the percent reticulocytes per 1,000 RBCs. The percent value was multiplied by the RBC count to determine the absolute number of reticulocytes per microliter of blood.
Necropsy and Handling of Tissue
Imaging Procedures Subepiphyseal and epiphyseal bone densities for each bone were measured using ImageJ software (National Institutes of Health) based on the pixel intensity over an area of 30 x 20 pixels. Bone densities for the proximal tibia were measured over an area of 100 x 200 pixels. The ratio of the epiphyseal density to the subepiphyseal density was then calculated for each bone.
Trimming of Tissue from Animals Sacrificed on Day 4 All of the prepared tissue sections were examined microscopically, and several were chosen for special staining. Phosphotungstic acid-hematoxylin (PTAH) stain was used to illustrate fibrin in the thrombi as previously demonstrated (Momotani et al., 1985; Halvorsen et al., 1994). Matching sections from control animals were also taken for staining.
Trimming of Tissue from Animals Sacrificed on Day 30 Upon histological examination, photographs were taken, and the width of the growth plate was measured in the head of the femur, distal femur, proximal tibia, and lumbar vertebra using ImageJ software (National Institutes of Health) for a control and an animal treated with 250 mg/kg/day BE. A micrometer was used to calibrate the measurements.
Statistical Analysis The Mann–Whitney–Wilcoxon nonparametric test was used to analyze parameters from the radiographic measurements. Because of the small sample size, only 2 bones were selected for statistical analysis. Due to the consistency in the lesions seen in the X-ray images, the lumbar vertebrae and the calcaneus bones were chosen. The ratio of the epiphyseal density to the subepiphyseal density was analyzed for these bones, comparing treated animals to controls.
Clinical Signs and Body Weights All of the treated animals began to have red-stained bedding 1 day after the first dose was given; this coloration continued for 1 to 2 days. The treated animals all also began to have a darkened discoloration on the tip of the tail on day 3, which became worse over time (Figures 1a–1b); 2 of the treated animals had lost the tip by 3 weeks. None of the control animals experienced any abnormal clinical signs throughout the study period.
All test animals sacrificed following the final dose on day 4 experienced an 8–16% decrease in body weight at the scheduled necropsy date. A statistically significant decrease occurred in mean body weight from the initiation of the experiment and the termination on day 4 for each of the treated groups compared to the control group (p < 0.05). No dose-related decrease in mean body weight occurred between the 2 treatment groups. In addition, 2 out of the 5 animals from the 250 mg/kg/day dose group (group 2) and 4 out of the 5 animals from the 300 mg/kg/day dose group (group 3) died before their scheduled necropsy date on day 4 (Table 1). These animals experienced a 6.8–12.6% decrease in body weight between the beginning of the experiment and their death. The animals in group 3 that died early were included in the histological examination. The animals in group 2 that died early were not included due to autolysis and inability to examine the tissue histopathologically. The treated animals sacrificed at day 30 experienced a loss in body weight during the treatment period but then recovered, experiencing an overall gain in weight during the course of the study. Four of the 5 animals from the 300 mg/kg/day dose group (Group 6) died before their scheduled necropsy date on day 30. Two of these animals died on day 4 and were included in the histological examination with the animals from Group 3 (Table 1).
Hematology for Animals Sacrificed on Day 4
Macroscopic Abnormalities The only common finding among the treated animals sacrificed on day 30 was a darkened purple-red discoloration on the distal third of the tail, which was noted in all 3 treated animals sacrificed on that day.
Histopathological Findings for Animals Sacrificed on Day 4 Bone changes were in agreement with previously described findings (Nyska et al., 1999b), and are summarized in Table 2. Growth plate alterations, such as those observed in the tail vertebra, consisted of degeneration of chondrocytes in the proliferative zone and early hypertrophied zone. Areas of degeneration exhibited a loss of chondrocytes, pallor of the cartilage matrix, and granularity and/or fragmentation with fibrillation. Chondrocytes located immediately adjacent to the degenerate areas were often disorganized, resulting in distortion of growth plate architecture.
Some of the osteocyte lacunae in the cortical and trabecular bone of both the femur and the coccygeal vertebrae showed apoptotic bodies or were empty. Most of the thrombi in the femur occurred near the stifle joint and were intramedullary, whereas most of the thrombi in the coccygeal vertebrae occurred in the periosteal and subcutaneous tissue. No positive identification of fibrin by PTAH staining was observed in any of the control animals.
X-Ray Image Analysis and Histopathological Findings for Animals Sacrificed on Day 30
Histological examination revealed lesions in treated animals in all of the bones examined (Table 2). No lesions were observed in the control animals. The bones most consistently affected histologically were the distal coccygeal vertebrae and the calcaneus bones (Figures 5a–5d, 7a–7d). The distal coccygeal vertebrae manifested the most severe damage, which corresponded to the clinical signs of the treated rats. Histopathology consisted of severe regional ischemia (usually the central region) of the growth plate, as described previously (Nyska et al., 1999b). These histological changes caused the radiolucency in the subepiphyseal area. Measurements showed a thinning in some growth plates of the treated animals, compared to controls, which was also noted during histological examination (Table 2). In vertebra where thinning of growth plate was noted (e.g., lumbar vertebra, tibia), all layers were present, without apparent loss of cells.
In agreement with previous studies (Ezov et al., 2002), our research demonstrated that BE induces acute hemolytic anemia, disseminated thrombosis, and bone infarction in female F344 rats at doses of 250 mg/kg/day and 300 mg/kg/day administered for 4 days and premature closure and infarction of growth plates in 30 days, or 26 days after the final treatment. Through special staining, we confirmed the presence of antemortem fibrin thrombi. Extensive bone necrosis was also found; empty osteocytic lacunae served as our diagnostic criterion (Nyska et al., 1999b; Zhao et al., 2000; Ezov et al., 2002; Shabat et al., 2004). We also demonstrated that the Faxitron Radiography System is effective in producing high-magnification images of bone lesions that can be correlated with histopathological changes. The Faxitron was not used in the animals sacrificed on day 4, because the changes in opacity due to bone pathology can only be detected after a few weeks when loss of bone, deposition of woven bone, and/or calcification occur (Imhof et al., 1997). The cause of death was most likely attributable to the severe anemia, hypoxia, and/or thrombosis induced by BE. One of the objectives of this experiment was to test if an increased dose of 300 mg/kg would result in more widespread and severe alterations secondary to thrombosis, without increasing mortality. Because such a high number of the rats receiving this dose died early in the study, 300 mg/kg/day was proven to be above the maximum tolerated dose. In addition, because no noticeable differences in the severity of the lesions were noted between the dosages, the 250 mg/kg/day BE was demonstrated to be an appropriate dose for this model. Previous experiments have indicated that this dose is effective in producing thrombosis with only sporadic cases of mortality, most likely related to severe anemia and hypoxia (Ezov et al., 2002). These studies also illustrated the necessity of administration of this high dose to induce this disseminated thrombotic crisis, the type that is also seen in sickle cell patients. The patterns of thrombosis seen in this study affirm previous studies claiming this to be an appropriate chemically induced animal model for researching human thrombotic disorders (Andrews et al., 1983; Cox and Soni, 1984; Smith, 1996; Nyska et al., 1999b; Eldor and Rachmilewitz, 2002; Ezov et al., 2002; Koshkaryev et al., 2003; Redlich et al., 2004; Shabat et al., 2004). Erythrocytes in humans with sickle cell anemia may be more prone to aggregation and vascular occlusion, leading to thrombosis (Obeifuna, 1991). Infarctive crisis is the most frequent form of sickle crisis, in which sickled erythrocytes obstruct small blood vessels in many organs, producing severe pain (Bonner and Erslev, 1994). In these patients, the skeleton is a frequent target of thrombosis and infarction, leading to bone and bone marrow infarction, as well as aseptic necrosis of various long bones (Hernigou et al., 1993; Smith, 1996; Hernigou et al., 1998; Kim and Miller, 2002; Hernigou et al., 2003). Disturbances in bone growth due to ischemia of the growth plate have been noted in sickle cell disease (Hernigou et al., 1993, 1998, 2003), other hemoglobinopathies (Johanson, 1990), and cases of local thrombosis induced accidentally in humans (DiFiori and Mandelbaum, 1996; Macnicol and Anagnostopoulos, 2000) or experimentally in animals (Beppu et al., 1989; Tamura et al., 1992; Hou et al., 1993; Shimizu et al., 1995; Kim et al., 2001; Matsuno et al., 2001). In the rats sacrificed 2 hours following the final BE treatment, thrombosis of the periosteal, cortical, and marrow blood vessels was confirmed. Damage to the growth plates of several bones was noted in the radiographs and subsequent histopathological examination of the treated rats sacrificed on day 30. Interesting findings in the treated animals sacrificed at 30 days that have not been previously demonstrated included a loss of the triradiate cartilage of the acetabulum and a premature closure of the growth plate of the calcaneus. Hip dysplasia is a common complication of sickle cell disease, and the pathogenesis is thought to involve direct damage to the triradiate cartilage (Hernigou et al., 1993). Hip osteonecrosis has become a significant cause of morbidity in sickle cell-disease patients, especially adults, and treatment options are extremely limited for this complication (Mandell and Meek, 1993; Reed and Vichinsky, 1998; Hernigou et al., 2003). Patients with sickle cell disease also may develop a pathognomonic calcaneal lesion related to avascular necrosis of the bone (Rothschild et al., 1997). These findings illustrate even more similarities between this animal model and human thrombotic diseases. The Faxitron Specimen Radiography System proved to be a useful tool for obtaining high-magnification X-ray images of various bones in the rats sacrificed after 30 days. The Faxitron has, along with a second imaging system, previously been used in mice to quantify the rate of bone healing (Li et al., 2001). It has also been used in imaging human fetuses (Bach-Petersen et al., 1995; Kjaer et al., 1998, 1999; Nolting et al., 1998). Unlike a previous MRI imaging of the bones, the Faxitron was able to distinguish the growth plates and bone diaphyses with high resolution (Shabat et al., 2004). Premature closure of the growth plate was found in many bones of the treated animals, including the coccygeal vertebrae, femur, proximal tibia, lumbar vertebrae, and calcaneus bones. That the Faxitron was also useful in locating areas of medullary necrosis in many of the bones was illustrated by a decreased radiographic density in the medullary cavity. The reason for this decrease was determined histologically to be necrosis in the cortical femur bone of 1 of the treated animals, diagnosed by the presence of empty osteocyte lacunae. A statistically significant increase occurred in the ratio of the epiphyseal density to the subepiphyseal density in the treated animals, compared to controls, for the lumbar vertebrae and the calcaneus bones. This occurrence was due to decreased radiographic density in the subepiphysis of the treated animals. In the animals examined acutely following BE treatment, thrombosis was found in the end arteries of the subepiphyseal area and in the cortical bone. The infarction of the growth plate due to the thrombosis would lead to deceleration of bone growth and a decrease in the radiographic density of the subepiphyseal area. That no bone thrombosis was observed in any of the animals examined at 30 days indicated that the ischemic episode was acute. This observation correlates with the findings of previous studies demonstrating that thrombi occurred only in animals sacrificed immediately following the final BE treatment, not in those given a recovery period (Ezov et al., 2002; Redlich et al., 2004; Shabat et al., 2004). The disturbances in growth plates seen only in those animals examined after 30 days correlate with abnormalities of human hemoglobinopathies, in which growth disturbances are frequently not seen until adolescence due to improved hematological management (Johanson, 1990). That the duration of ischemia is the most important determinant of pediatric growth plate disturbances has been demonstrated previously (Stark et al., 1987; Carey et al., 1990; Tamura et al., 1992; Hou et al., 1993; Shimizu et al., 1995; Sunagawa, 1996). At least 6 hours of ischemia are required before longitudinal growth is affected (Shimizu et al., 1995; Matsuno et al., 2001). The treated animals that were examined by radiography and subsequent histology had endured chronic ischemic injury as a result of the disseminated thrombosis induced by BE. This was illustrated grossly, in the appearance of the tails, as well as histologically. The severe hemolytic anemia induced by BE for at least 4–5 days could also have contributed to a reduction of normal proliferation in the growth plate, due to a decreased oxygen tension (Carey et al., 1990). In the coccygeal vertebrae, thrombosis of large vessels was identified in the animals sacrificed on day 4, and an infarction of the growth plate was seen in the animals sacrificed on day 30, or 26 days after the final treatment. Based on these findings, ischemia due to thrombosis most likely constituted the principal cause of reduced growth plate proliferation in this region. In the other articulations, however, the hemolytic anemia and reduced oxygen tension most likely led to the reduced growth. In future studies using this model, we plan to examine at 4 days those regions that were only examined chronically, such as the calcaneus and triradiate cartilage, to look for thrombosis. Normal growth plate chondrocytes undergo apoptosis to contribute to longitudinal bone growth (Hatori et al., 1995; Zenmyo et al., 1996). Ischemia and eventual reperfusion, however, lead to an increased rate of chondrocytic cell death by both apoptosis and necrosis (Matsuno et al., 2001). Ischemia lasting 48 hours causes death to chondrocytes due to interruption of the epiphyseal blood supply (Trutea and Amato, 1960). The severe anemia and thrombosis induced acutely by BE, demonstrated histologically in the rats sacrificed following the final dose, would lead to this ischemic damage. Those animals sacrificed after 30 days may also have been affected by reperfusion injury. During such injury, oxygen free radicals are produced, causing oxidative stress that may damage proliferating chondrocytes in epiphyseal growth plates, as well as cells in other organs and tissues (McCord, 1985; Weiss et al., 1989; Tamura et al., 1992; Yokoyama et al., 1993; Al-Qattan, 1998). The free radicals directly kill more chondrocytes by destruction of cellular membranes and also increase cellular death signals (Matsuno et al., 2001). The rate of cell death increases with increased ischemia time due to the production of more oxygen free radicals (Yokoyama et al., 1993). These events explain, in part, the pathogenesis of the lesions seen in the growth plates of these animals by both radiographical and histological examination. With such a length of time of ischemia experienced by these rats, however, other pathological alterations, such as residual changes in vascular patency, may also affect growth disturbances (Matsuno et al., 2001). Normal closure of growth plates in the rat occurs at 11 to 12 months, with the physis of long bones never completely resorbed (Leininger and Riley, 1990; Kilborn et al., 2002). The treated rats that were sacrificed at 30 days and examined by radiography were 15–16 weeks old at the time of sacrifice. Although the control animals were only 10–12 weeks old at the time of sacrifice, the closure seen in the growth plates of several bones by radiography and in the calcaneus and triradiate cartilage by histology is not due to this difference in age between the groups. The treated rats were too young to exhibit such a dramatic loss of epiphyseal cartilage. The measured decrease in width of the growth plate in the femur, tibia, and lumbar vertebra in the treated animal, compared to the control, however, would be more convincing had the rats been of the same age. In future experiments using this animal model, the treatment and control groups must be more carefully age-matched. This matching would also be more helpful in evaluating other measurements, such as the length and width of the bones. Additional investigations using this model are currently underway, aiming to identify blood biomarkers that reflect the hypercoagulable state occurring in these rats. These biomarkers can then be applied in testing drug efficacy for the acute thrombotic stage of this model. The lesions seen by the radiographic imaging correlated well with those seen by histological examination. The Faxitron specimen radiography system is a noninvasive tool that can be used in future studies to image the chronic effects of BE exposure on the skeletal system of female F344 rats, an animal model in which treatment modalities can be examined and applied to the chronic effects of a number of human hemolytic diseases associated with thrombotic alterations.
The authors thank JoAnne Johnson, Dr. Gordon Flake, and Dr. Hiroshi Satoh for critically reviewing this manuscript; those at ILS who assisted with this study, especially Dr. Glenda Moser and Theleria Hackett; and members of the histology staff at NIEHS, especially Natasha Clayton, Julie Foley, Tina Jones, Bettie Harris, and Denise Burwell, who provided outstanding technical expertise.
Toxicologic Pathology, Vol. 33, No. 2,
272-282 (2005)
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
TOP
Abstract
Materials and Methods
